Target Price | $96.88 |
Price | $59.09 |
Potential | 63.96% |
Number of Estimates | 26 |
26 Analysts have issued a price target Lam Research 2026 . The average Lam Research target price is $96.88. This is 63.96% higher than the current stock price. The highest price target is $125.00 111.54% , the lowest is $75.00 26.93% . | |
A rating was issued by 33 analysts: 23 Analysts recommend Lam Research to buy, 10 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lam Research stock has an average upside potential 2026 of 63.96% . Most analysts recommend the Lam Research stock at Purchase. |
26 Analysts have issued a sales forecast Lam Research 2025 . The average Lam Research sales estimate is $17.7b . This is 9.48% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $18.0b 10.86% , the lowest is $17.2b 6.09% .
This results in the following potential growth metrics:
2024 | $14.9b | 14.47% |
---|---|---|
2025 | $17.7b | 19.05% |
2026 | $18.3b | 2.93% |
2027 | $20.4b | 11.94% |
2028 | $24.0b | 17.49% |
2029 | $25.3b | 5.33% |
15 Analysts have issued an Lam Research EBITDA forecast 2025. The average Lam Research EBITDA estimate is $5.9b . This is 13.58% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.0b 16.21% , the lowest is $5.6b 7.11% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 16.82% |
---|---|---|
2025 | $5.9b | 25.71% |
2026 | $6.0b | 2.30% |
2027 | $7.1b | 17.28% |
2028 | $8.5b | 20.92% |
2029 | $9.3b | 8.33% |
2024 | 31.43% | 2.75% |
---|---|---|
2025 | 33.19% | 5.59% |
2026 | 32.99% | 0.60% |
2027 | 34.56% | 4.76% |
2028 | 35.57% | 2.92% |
2029 | 36.58% | 2.84% |
19 Lam Research Analysts have issued a net profit forecast 2025. The average Lam Research net profit estimate is $4.8b . This is 14.13% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.9b 17.02% , the lowest is $4.7b 10.64% .
This results in the following potential growth metrics and future Net Margins:
2024 | $3.7b | 12.65% |
---|---|---|
2025 | $4.8b | 29.48% |
2026 | $4.9b | 2.38% |
2027 | $6.0b | 20.81% |
2028 | $7.1b | 18.43% |
2029 | $8.3b | 18.00% |
2024 | 25.00% | 2.12% |
---|---|---|
2025 | 27.19% | 8.76% |
2026 | 27.04% | 0.55% |
2027 | 29.19% | 7.95% |
2028 | 29.42% | 0.79% |
2029 | 32.96% | 12.03% |
19 Analysts have issued a Lam Research forecast for earnings per share. The average Lam Research EPS is $3.75 . This is 13.98% higher than earnings per share in the financial year 2024. The highest EPS forecast is $3.85 17.02% , the lowest is $3.64 10.64% .
This results in the following potential growth metrics and future valuations:
2024 | $2.90 | 12.65% |
---|---|---|
2025 | $3.75 | 29.31% |
2026 | $3.84 | 2.40% |
2027 | $4.64 | 20.83% |
2028 | $5.50 | 18.53% |
2029 | $6.49 | 18.00% |
Current | 17.96 | 52.18% |
---|---|---|
2025 | 15.74 | 12.36% |
2026 | 15.37 | 2.35% |
2027 | 12.72 | 17.24% |
2028 | 10.74 | 15.57% |
2029 | 9.10 | 15.27% |
Based on analysts' sales estimates for 2025, the Lam Research stock is valued at an EV/Sales of 4.24 and an P/S ratio of 4.27 .
This results in the following potential growth metrics and future valuations:
Current | 4.64 | 47.57% |
---|---|---|
2025 | 4.24 | 8.71% |
2026 | 4.12 | 2.85% |
2027 | 3.68 | 10.66% |
2028 | 3.13 | 14.89% |
2029 | 2.97 | 5.06% |
Current | 4.68 | 47.40% |
---|---|---|
2025 | 4.27 | 8.66% |
2026 | 4.15 | 2.85% |
2027 | 3.71 | 10.66% |
2028 | 3.16 | 14.89% |
2029 | 3.00 | 5.06% |
Analyst | Rating | Action | Date |
---|---|---|---|
Jefferies |
Buy
➜
Buy
|
Unchanged | Mar 28 2025 |
Susquehanna |
Neutral
➜
Positive
|
Upgrade | Feb 20 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Feb 20 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Feb 20 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Feb 18 2025 |
Needham |
Buy
➜
Buy
|
Unchanged | Jan 30 2025 |
Cantor Fitzgerald |
Neutral
➜
Overweight
|
Upgrade | Jan 30 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Jefferies:
Buy
➜
Buy
|
Mar 28 2025 |
Upgrade
Susquehanna:
Neutral
➜
Positive
|
Feb 20 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Feb 20 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Feb 20 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Feb 18 2025 |
Unchanged
Needham:
Buy
➜
Buy
|
Jan 30 2025 |
Upgrade
Cantor Fitzgerald:
Neutral
➜
Overweight
|
Jan 30 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.